COVID-19 depressive and anxiety disorders, cannabidiol, mortality in people with mental disorders and intellectual disabilities during COVID-19

Peer reviewed journals featured:

- A systematic review on global prevalence and burden of depressive and anxiety disorders due to COVID-19 [here](#) and associated commentary [here](#)
- A randomised controlled trial on cannabidiol for mild to moderate COVID-19 patients [here](#)
- Observational studies on:
  - All-cause and cause-specific mortality in people with mental disorders and intellectual disabilities during COVID-19 in the UK [here](#)
  - Natural spring water gargle and direct RT-PCR for COVID-19 diagnosis [here](#)
  - Risks of SARS-CoV-2 infection among children and adults in Utah and New York [here](#) and associated editorial [here](#)

Letters and correspondence discussed:

- SARS-CoV-2 and respiratory syncytial virus (RSV) in pre-schoolers and infants [here](#)
- D-dimer testing for the exclusion of pulmonary embolism in hospitalised COVID-19 patients [here](#)

Pre-peer review featured articles:

- COVID-19 vaccine effectiveness by product and timing in New York [here](#)
- The COVIDNearTerm method to forecast COVID-19 hospitalisations [here](#)
- Comprehensive antibody profiling of mRNA vaccination in children [here](#)

Guidance and reports:

- The World Health Organization published:
  - Updates to its COVID-19 vaccine tracker [here](#)
  - Articles in the Bulletin of the WHO on:
    - Pooled testing for SARS-CoV-2 [here](#)
    - Vaccine recommendations for pregnancy [here](#)
    - Violence against children during COVID-19 [here](#)
News and blogs

• Heart-inflammation risk from Comirnart (Pfizer) vaccine is very low here
• How antiviral pill molnupiravir shot ahead in the COVID-19 drug hunt here
• Nature podcast on the benefits of air filters and masks here

Click here to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on COVID-19 transmission, SARS-CoV-2 vaccines, and variants of concern, post-acute sequelae of COVID-19 (PASC), surgery and COVID-19, rapid testing and risk mitigation strategies.